BUZZ-Gyre Therapeutics 股票发行后暴跌

路透中文

May 23, 2025

BUZZ-<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> 股票发行后暴跌

5月22日 - ** Gyre Therapeutics GYRE.O股价盘后下跌17.5%，至9.25美元，该公司正寻求股票融资

** 总部位于圣地亚哥的生物技术公司开始发行股票 (link)；交易规模未披露

** 该公司打算将募集资金净额用于推进 F351 治疗代谢障碍的第二阶段试验。 F351 用于代谢功能障碍相关性脂肪性肝炎("MASH")- 相关性肝纤维化的第二阶段试验，用于研发和生产等其他用途。

** 杰富瑞（Jefferies）是此次发行的主要簿记管理人

** 公司还称 (link) F351 在评估治疗中国慢性乙型肝炎患者肝纤维化的有效性和安全性的关键性 III 期临床试验中达到了主要终点。

** 公司已发行股票约 9,380 万股，市值约 10 亿美元

** GYRE 周四收盘上涨 8.1%，报 11.21 美元，将今年以来的亏损降至 ~7%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537927835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537927835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537927835?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-23 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537927835","market":"us","top_or_hot":-1,"title":"BUZZ-Gyre Therapeutics 股票发行后暴跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> 股票发行后暴跌</title></head><body><p><span>5月22日</span><span> - </span>** Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>GYRE.O</span>股价盘后下跌17.5%，至9.25美元，该公司正寻求股票融资 </p><p>** 总部位于圣地亚哥的生物技术公司开始发行股票 (link)；交易规模未披露</p><p>** 该公司打算将募集资金净额用于推进 F351 治疗代谢障碍的第二阶段试验。 <span>F351 用于代谢功能障碍相关性脂肪性肝炎(\"MASH\")- 相关性肝纤维化的第二阶段试验，用于研发和生产等其他用途。</span></p><p><span>** <a href=\"https://laohu8.com/S/JEF\">杰富瑞</a>（Jefferies）是此次发行的主要簿记管理人</span></p><p>** 公司还称 (link) <span>F351 在评估治疗中国慢性乙型肝炎患者肝纤维化的有效性和安全性的关键性 III 期临床试验中达到了主要终点。</span></p><p>** 公司已发行股票约 9,380 万股，市值约 10 亿美元</p><p>** GYRE 周四收盘上涨 8.1%，报 11.21 美元，将今年以来的亏损降至 ~7%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Gyre Therapeutics 股票发行后暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Gyre Therapeutics 股票发行后暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-05-23 04:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> 股票发行后暴跌</title></head><body><p><span>5月22日</span><span> - </span>** Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>GYRE.O</span>股价盘后下跌17.5%，至9.25美元，该公司正寻求股票融资 </p><p>** 总部位于圣地亚哥的生物技术公司开始发行股票 (link)；交易规模未披露</p><p>** 该公司打算将募集资金净额用于推进 F351 治疗代谢障碍的第二阶段试验。 <span>F351 用于代谢功能障碍相关性脂肪性肝炎(\"MASH\")- 相关性肝纤维化的第二阶段试验，用于研发和生产等其他用途。</span></p><p><span>** <a href=\"https://laohu8.com/S/JEF\">杰富瑞</a>（Jefferies）是此次发行的主要簿记管理人</span></p><p>** 公司还称 (link) <span>F351 在评估治疗中国慢性乙型肝炎患者肝纤维化的有效性和安全性的关键性 III 期临床试验中达到了主要终点。</span></p><p>** 公司已发行股票约 9,380 万股，市值约 10 亿美元</p><p>** GYRE 周四收盘上涨 8.1%，报 11.21 美元，将今年以来的亏损降至 ~7%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nL4S3RU1KS:1","article_id":"2537927835","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537927835","pubTimestamp":1747946271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Gyre Therapeutics 股票发行后暴跌5月22日 - ** Gyre Therapeutics GYRE.O股价盘后下跌17.5%，至9.25美元，该公司正寻求股票融资 ** 总部位于圣地亚哥的生物技术公司开始发行股票 ；交易规模未披露** 该公司打算将募集资金净额用于推进 F351 治疗代谢障碍的第二阶段试验。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GYRE":"Gyre Therapeutics","BK4127":"投资银行业与经纪业","BK4559":"巴菲特持仓","JEF":"杰富瑞"},"translate_title":"BUZZ-Gyre Therapeutics Stock Plunges After Offering","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JEF":0.9,"GYRE":0.9},"content_text":"BUZZ-Gyre Therapeutics 股票发行后暴跌5月22日 - ** Gyre Therapeutics GYRE.O股价盘后下跌17.5%，至9.25美元，该公司正寻求股票融资 ** 总部位于圣地亚哥的生物技术公司开始发行股票 (link)；交易规模未披露** 该公司打算将募集资金净额用于推进 F351 治疗代谢障碍的第二阶段试验。 F351 用于代谢功能障碍相关性脂肪性肝炎(\"MASH\")- 相关性肝纤维化的第二阶段试验，用于研发和生产等其他用途。** 杰富瑞（Jefferies）是此次发行的主要簿记管理人** 公司还称 (link) F351 在评估治疗中国慢性乙型肝炎患者肝纤维化的有效性和安全性的关键性 III 期临床试验中达到了主要终点。** 公司已发行股票约 9,380 万股，市值约 10 亿美元** GYRE 周四收盘上涨 8.1%，报 11.21 美元，将今年以来的亏损降至 ~7%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}